{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T04:58:40Z","timestamp":1790398720197,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.autrev.2017.03.007","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T07:18:03Z","timestamp":1488871083000},"page":"495-503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":146,"title":["Modulation of sphingosine-1-phosphate in inflammatory bowel disease"],"prefix":"10.1016","volume":"16","author":[{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"Christopher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Behan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.autrev.2017.03.007_bb0005","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1136\/gutjnl-2011-300049","article-title":"Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health","volume":"61","author":"Peyrin-Biroulet","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2017.03.007_bb0010","author":"ECCO"},{"key":"10.1016\/j.autrev.2017.03.007_bb0015","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.dld.2016.01.011","article-title":"Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months \u2013 multicenter European cohort study","volume":"48","author":"Van Assche","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2017.03.007_bb0020","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1517\/13543784.2016.1165204","article-title":"Will novel oral formulations change the management of inflammatory bowel disease?","volume":"25","author":"Nielsen","year":"2016","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.autrev.2017.03.007_bb0025","first-page":"72","article-title":"Inflammatory bowel disease","volume":"113","author":"Wehkamp","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.autrev.2017.03.007_bb0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.09.018","article-title":"Subcutaneous ustekinumab provides clinical benefit for two-thirds of patients with Crohn\u2019s disease refractory to anti-tumor necrosis factor agents","volume":"14","author":"Wils","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0035","author":"Janssen Biotech Incorporated"},{"key":"10.1016\/j.autrev.2017.03.007_bb0040","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.dld.2016.01.013","article-title":"Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: a real world-based study","volume":"48","author":"Peyrin-Biroulet","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.autrev.2017.03.007_bb0045","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1111\/apt.12507","article-title":"Review article: immunogenicity of anti-TNF biologics in IBD \u2013 the role of patient, product and prescriber factors","volume":"38","author":"Moss","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2017.03.007_bb0050","doi-asserted-by":"publisher","first-page":"81","DOI":"10.4103\/1319-3767.129473","article-title":"Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties","volume":"20","author":"Mosli","year":"2014","journal-title":"Saudi J Gastroenterol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0055","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1136\/gutjnl-2012-303376","article-title":"Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNF\u03b1 therapy: results from the COIN study","volume":"63","author":"Van der Valk","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2017.03.007_bb0060","article-title":"Next generation of small molecules in inflammatory bowel disease","author":"Olivera","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2017.03.007_bb0065","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1194\/jlr.R046300","article-title":"An update on the biology of sphingosine 1-phosphate receptors","volume":"55","author":"Blaho","year":"2014","journal-title":"J Lipid Res"},{"key":"10.1016\/j.autrev.2017.03.007_bb0070","author":"Spiegel"},{"key":"10.1016\/j.autrev.2017.03.007_bb0075","article-title":"Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease","author":"Karuppuchamy","year":"2016","journal-title":"Mucosal Immunol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0080","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.yjmcc.2009.10.009","article-title":"FTY720 prevents ischemia\/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1\/Akt signaling","volume":"48","author":"Egom","year":"2010","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0085","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1096\/fj.05-3730fje","article-title":"Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration","volume":"19","author":"Wang","year":"2005","journal-title":"FASEB J"},{"issue":"9","key":"10.1016\/j.autrev.2017.03.007_bb0090","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/1742-2094-9-133","article-title":"Sphingosine 1-phosphate receptor 5 mediates the immune quiescence of the human brain endothelial barrier","volume":"20","author":"van Doorn","year":"2012","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.autrev.2017.03.007_bb0095","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0052985","article-title":"The clinically-tested S1P receptor agonists, FTY720 and BAF312, demonstrate subtype-specific bradycardia (S1P\u2081) and hypertension (S1P\u2083) in rat","volume":"7","author":"Fryer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.03.007_bb0100","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1152\/physiolgenomics.00053.2012","article-title":"Expression of sphingosine 1-phosphate receptors in the rat dorsal root ganglia and defined single isolated sensory neurons","volume":"44","author":"Kays","year":"2012","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.autrev.2017.03.007_bb0105","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017268","article-title":"Genetic evidence for involvement of neuronally expressed S1P1 receptor in nociceptor sensitization and inflammatory pain","volume":"6","author":"Mair","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2017.03.007_bb0110","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.2353\/ajpath.2010.100220","article-title":"High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1\/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients","volume":"177","author":"Watson","year":"2010","journal-title":"Am J Pathol"},{"issue":"21","key":"10.1016\/j.autrev.2017.03.007_bb0115","doi-asserted-by":"publisher","first-page":"14839","DOI":"10.1074\/jbc.M112.426726","article-title":"Sphingosine 1-phosphate (S1P) receptor agonists mediate pro-fibrotic responses in normal human lung fibroblasts via S1P2 and S1P3 receptors and Smad-independent signaling","volume":"288","author":"Sobel","year":"2013","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2017.03.007_bb0120","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1124\/mol.114.097261","article-title":"FTY720 phosphate activates sphingosine-1-phosphate receptor 2 and selectively couples to G\u03b112\/13\/Rho\/ROCK to induce myofibroblast contraction","volume":"87","author":"Sobel","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0125","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1111\/j.1600-6143.2004.00476.x","article-title":"FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function","volume":"4","author":"Brinkmann","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.autrev.2017.03.007_bb0130","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1111\/bph.13476","article-title":"Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1) and receptor-5 (S1P5) agonist with autoimmune disease-modifying activity","volume":"173","author":"Scott","year":"2016","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0135","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1523\/JNEUROSCI.4479-12.2013","article-title":"Sphingosine-1-phosphate-induced nociceptor excitation and ongoing pain behavior in mice and humans is largely mediated by S1P3 receptor","volume":"33","author":"Camprub\u00ed-Robles","year":"2013","journal-title":"J Neurosci"},{"issue":"132","key":"10.1016\/j.autrev.2017.03.007_bb0140","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1002\/ijc.27692","article-title":"Identification of novel functional and spatial associations between sphingosine kinase 1, sphingosine 1-phosphate receptors and other signaling proteins that affect prognostic outcome in estrogen receptor-positive breast cancer","volume":"2013","author":"Ohotski","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.autrev.2017.03.007_bb0145","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3389\/fphar.2016.00167","article-title":"Sphingosine-1-phosphate receptor-2 antagonists: therapeutic potential and potential risks","volume":"7","author":"Blankenbach","year":"2016","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0150","doi-asserted-by":"publisher","first-page":"G605","DOI":"10.1152\/ajpgi.00147.2006","article-title":"Characterization of S1P1 and S1P2 receptor function in smooth muscle by receptor silencing and receptor protection","volume":"291","author":"Hu","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0155","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.ejphar.2013.10.004","article-title":"Sphingosine-1-phosphate induced contraction of bladder smooth muscle","volume":"720","author":"Kendig","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0160","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S0008-6363(03)00260-8","article-title":"Sphingosine 1-phosphate induces contraction of coronary artery smooth muscle cells via S1P2","volume":"58","author":"Ohmori","year":"2003","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.autrev.2017.03.007_bb0165","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1681\/ASN.2011050503","article-title":"Inhibition of sphingosine 1-phosphate receptor 2 protects against renal ischemia-reperfusion injury","volume":"23","author":"Park","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0170","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1124\/mol.115.097857","article-title":"G protein-coupled receptor and RhoA-stimulated transcriptional responses: links to inflammation, differentiation, and cell proliferation","volume":"88","author":"Yu","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0175","doi-asserted-by":"publisher","first-page":"8686","DOI":"10.1158\/0008-5472.CAN-09-1110","article-title":"Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation","volume":"69","author":"Cattoretti","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2017.03.007_bb0180","article-title":"Acid ceramidase induces sphingosine kinase 1\/S1P receptor 2-mediated activation of oncogenic Akt signaling","volume":"2","author":"Beckham","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.autrev.2017.03.007_bb0185","doi-asserted-by":"publisher","first-page":"4024","DOI":"10.1096\/fj.10-179028","article-title":"Sphingosine-1-phospate receptor 4 (S1P\u2084) deficiency profoundly affects dendritic cell function and TH17-cell differentiation in a murine model","volume":"25","author":"Schulze","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.autrev.2017.03.007_bb0190","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1038\/bjc.2012.98","article-title":"Expression of sphingosine 1-phosphate receptor 4 and sphingosine kinase 1 is associated with outcome in oestrogen receptor-negative breast cancer","volume":"106","author":"Ohotski","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.autrev.2017.03.007_bb0195","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1096\/fj.06-7420com","article-title":"Activation of sphingosine-1-phosphate receptor S1P5 inhibits oligodendrocyte progenitor migration","volume":"21","author":"Novgorodov","year":"2007","journal-title":"FASEB J"},{"key":"10.1016\/j.autrev.2017.03.007_bb0200","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1523\/JNEUROSCI.4645-04.2005","article-title":"Edg8\/S1P5: an oligodendroglial receptor with dual function on process retraction and cell survival","volume":"25","author":"Jaillard","year":"2005","journal-title":"J Neurosci"},{"key":"10.1016\/j.autrev.2017.03.007_bb0205","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/ni1523","article-title":"Natural killer cell trafficking in vivo requires a dedicated sphingosine1-phosphate receptor","volume":"8","author":"Walzer","year":"2007","journal-title":"Nat Immunol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0210","doi-asserted-by":"publisher","first-page":"4863","DOI":"10.1182\/blood-2011-06-362574","article-title":"Sequential desensitization of CXCR4 and S1P5 controls natural killer cell trafficking","volume":"118","author":"Mayol","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2017.03.007_bb0215","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/WNF.0b013e3181cbf825","article-title":"Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis","volume":"33","author":"Chun","year":"2010","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0220","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0014-5793(02)03404-X","article-title":"Embryonic brain expression analysis of lysophospholipid receptor genes suggests roles for s1p(1) in neurogenesis and s1p(1\u20133) in angiogenesis","volume":"531","author":"McGiffert","year":"2002","journal-title":"FEBS Lett"},{"key":"10.1016\/j.autrev.2017.03.007_bb0225","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/nchembio.1611","article-title":"Endosomal generation of cAMP in GPCR signaling","volume":"10","author":"Vilardaga","year":"2014","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0230","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.03.007_bb0235","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","article-title":"A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis","volume":"362","author":"Kappos","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.03.007_bb0240","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S1474-4422(14)70049-3","article-title":"Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomized, placebo-controlled, phase 3 trial","volume":"13","author":"Calabresi","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0255","series-title":"Poster P01.158 presented at American Academy of Neurology (AAN) annual meeting 2013, San Diego, USA","article-title":"The preclinical safety profile of RPC1063, a selective and potent sphingosine 1-phosphate 1 receptor (S1P1R) modulator","author":"Peach","year":"2013"},{"key":"10.1016\/j.autrev.2017.03.007_bb0260","series-title":"Presented at: United European gastroenterology week (UEGW)","article-title":"Receptor profile and efficacy of etrasimod (APD334), an oral, next-generation sphingosine-1-phosphate receptor modulator in development for ulcerative colitis","author":"Peyrin-Biroulet","year":"2016"},{"issue":"7","key":"10.1016\/j.autrev.2017.03.007_bb0265","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40263-015-0261-z","article-title":"Sphingosine 1-phosphate receptor modulators in multiple sclerosis","volume":"29","author":"Subei","year":"2015","journal-title":"CNS Drugs"},{"key":"10.1016\/j.autrev.2017.03.007_bb0275","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1136\/jnnp-2013-307282","article-title":"Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial","volume":"85","author":"Olsson","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2017.03.007_bb0280","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1016\/S0140-6736(14)60803-5","article-title":"Oral ponesimod in patients with chronic plaque psoriasis: a randomised, double-blind, placebo-controlled phase 2 trial","volume":"384","author":"Vaclavkova","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2017.03.007_bb0285","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/S1474-4422(13)70102-9","article-title":"Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study","volume":"12","author":"Selmaj","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0290","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.autrev.2017.03.007_bb0295","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(16)00018-1","article-title":"Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial","volume":"15","author":"Cohen","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0300","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.autrev.2017.03.007_bb0305","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1016\/S1474-4422(16)30192-2","article-title":"Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial","volume":"15","author":"Kappos","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0310","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1002\/cpdd.98","article-title":"Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers","volume":"3","author":"Xu","year":"2014","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.autrev.2017.03.007_bb0315","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/j.1476-5381.2012.02061.x","article-title":"The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate","volume":"167","author":"Gergely","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0320","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bcp.12129","article-title":"Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P receptor modulator, in the first-in-human study","volume":"76","author":"Brossard","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0325","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1111\/j.1365-2125.2003.02065.x","article-title":"Single-dose FTY720 pharmacokinetics, food effect, and pharmacological responses in healthy subjects","volume":"57","author":"Kovarik","year":"2004","journal-title":"Br J Clin Pharmacol"},{"issue":"Pt A","key":"10.1016\/j.autrev.2017.03.007_bb0330","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.phrs.2016.09.025","article-title":"To fingolimod and beyond: the rich pipeline of drug candidates that target S1P signaling","volume":"113","author":"Chew","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.autrev.2017.03.007_bb0335","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.autrev.2017.03.007_bb0340","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1016\/j.molimm.2007.02.026","article-title":"FTY720 ameliorates oxazolone colitis in mice by directly affecting T helper type 2 functions","volume":"44","author":"Daniel","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2017.03.007_bb0345","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.autrev.2017.03.007_bb0350","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.autrev.2017.03.007_bb0360","series-title":"Press release. Biogen reports record third quarter 2016 revenues of $3.0 billion","author":"Biogen","year":"2016"},{"key":"10.1016\/j.autrev.2017.03.007_bb0365","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMoa1513248","article-title":"Ozanimod induction and maintenance treatment for ulcerative colitis","volume":"374","author":"Sandborn","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2017.03.007_bb0370","series-title":"Poster presented at: United European gastroenterology week (UEGW)","article-title":"Effects of high- and low-fat meals on the pharmacokinetics of oxanimod, a novel sphingosine 1-phsophate receptor modulator","author":"Tran","year":"2016"},{"issue":"5 Suppl","key":"10.1016\/j.autrev.2017.03.007_bb0375","article-title":"Safety and efficacy of long-term treatment with ozanimod, and oral S1P receptor modulator, in moderate to severe ulcerative colitis: TOUCHSTONE extension","volume":"4","author":"Sandborn","year":"2016","journal-title":"UEG J"},{"key":"10.1016\/j.autrev.2017.03.007_bb0380","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.autrev.2017.03.007_bb0385","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.autrev.2017.03.007_bb0390","author":"Arena Pharmaceuticals"},{"key":"10.1016\/j.autrev.2017.03.007_bb0395","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.autrev.2017.03.007_bb0400","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.autrev.2017.03.007_bb0405","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.msard.2016.04.002","article-title":"Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS)","volume":"8","author":"Meissner","year":"2016","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.autrev.2017.03.007_bb0410","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1517\/14740338.2015.1093620","article-title":"Risk of progressive multifocal leukoencephalopathy in patients with multiple sclerosis","volume":"14","author":"Faulkner","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.autrev.2017.03.007_bb0415","author":"Medicines and Healthcare products Regulatory Agency"},{"key":"10.1016\/j.autrev.2017.03.007_bb0420","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1177\/1352458515596458","article-title":"Assessing PML risk under immunotherapy: if all you have is a hammer, everything looks like a nail","volume":"22","author":"Van Schependom","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.autrev.2017.03.007_bb0425","doi-asserted-by":"publisher","first-page":"13839","DOI":"10.1074\/jbc.M311743200","article-title":"Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate","volume":"279","author":"Sanna","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2017.03.007_bb0430","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.ahj.2014.06.028","article-title":"Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications","volume":"168","author":"Camm","year":"2014","journal-title":"Am Heart J"},{"key":"10.1016\/j.autrev.2017.03.007_bb0435","author":"Clinicaltrials.gov"},{"key":"10.1016\/j.autrev.2017.03.007_bb0440","series-title":"Presented at: Advances in inflammatory bowel diseases (AIBD)","article-title":"Etrasimod (APD334), a potent, selective, oral S1P receptor modulator with autoimmune disease-modifying activity that exhibits favourable PK\/PD properties in healthy volunteers","author":"Schreiber","year":"2016"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217300605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997217300605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,25]],"date-time":"2022-07-25T08:19:30Z","timestamp":1658737170000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997217300605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1568997217300605"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2017.03.007","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Modulation of sphingosine-1-phosphate in inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2017.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}